OCUGEN, INC. Increase Decrease In Operating Lease Liability
OCUGEN, INC. (OCGN) reported Increase Decrease In Operating Lease Liability of -$635.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- OCUGEN, INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$318.00K.
- OCUGEN, INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$317.00K.
- OCUGEN, INC. increase decrease in operating lease liability for the quarter ending 2025-06-30 was -$401.00K.
- OCUGEN, INC. increase decrease in operating lease liability for the quarter ending 2025-03-31 was -$195.00K.
- OCUGEN, INC. increase decrease in operating lease liability for fiscal 2025 was -$1.23M.
- OCUGEN, INC. increase decrease in operating lease liability for fiscal 2024 was -$833.00K.
- OCUGEN, INC. increase decrease in operating lease liability for fiscal 2023 was -$517.00K.
- OCUGEN, INC. increase decrease in operating lease liability for fiscal 2022 was -$383.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$318.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$635.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | -$317.00K 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | -$1.23M 10-K · filed 2026-03-04 | |||
| 2025-06-30 | -$401.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$596.00K 10-Q · filed 2026-08-06 | -$812.00K derived: sum of 3 quarters · filed 2026-08-06 | -$1.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$195.00K 10-Q · filed 2026-05-08 | -$411.00K derived: sum of 2 quarters · filed 2026-05-08 | -$806.00K derived: sum of 3 quarters · filed 2026-05-08 | -$889.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$216.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$611.00K derived: sum of 2 quarters · filed 2026-03-04 | -$694.00K derived: sum of 3 quarters · filed 2026-03-04 | -$833.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | -$395.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$478.00K derived: sum of 2 quarters · filed 2025-08-04 | -$617.00K 10-Q · filed 2024-11-14 | -$752.00K derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-06-30 | -$83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$222.00K 10-Q · filed 2025-08-04 | -$357.00K derived: sum of 3 quarters · filed 2025-08-04 | -$487.00K derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-03-31 | -$139.00K 10-Q · filed 2025-05-09 | -$274.00K derived: sum of 2 quarters · filed 2025-05-09 | -$404.00K derived: sum of 3 quarters · filed 2025-05-09 | -$531.00K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$265.00K derived: sum of 2 quarters · filed 2025-03-05 | -$392.00K derived: sum of 3 quarters · filed 2025-03-05 | -$517.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | -$130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$257.00K derived: sum of 2 quarters · filed 2024-11-14 | -$382.00K 10-Q · filed 2024-11-14 | -$504.00K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$252.00K 10-Q · filed 2024-08-08 | -$374.00K derived: sum of 3 quarters · filed 2024-08-08 | -$370.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$125.00K 10-Q · filed 2024-05-14 | -$247.00K derived: sum of 2 quarters · filed 2024-05-14 | -$243.00K derived: sum of 3 quarters · filed 2024-05-14 | -$332.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$122.00K derived: 10-K 12 month − 10-K 9 month · filed 2024-04-16 | -$118.00K derived: sum of 2 quarters · filed 2024-04-16 | -$207.00K derived: sum of 3 quarters · filed 2024-04-16 | -$383.00K 10-K · filed 2024-04-16 |
| 2022-09-30 | $4.00K derived: 10-K 9 month − 10-K 6 month · filed 2024-04-16 | -$85.00K derived: sum of 2 quarters · filed 2024-04-16 | -$261.00K 10-K · filed 2024-04-16 | -$436.00K derived: sum of 4 quarters · filed 2024-04-16 |
| 2022-06-30 | -$89.00K derived: 10-K 6 month − 10-K 3 month · filed 2024-04-16 | -$265.00K 10-K · filed 2024-04-16 | -$440.00K derived: sum of 3 quarters · filed 2024-04-16 | -$501.00K derived: sum of 4 quarters · filed 2024-04-16 |
| 2022-03-31 | -$176.00K 10-K · filed 2024-04-16 | -$351.00K derived: sum of 2 quarters · filed 2024-04-16 | -$412.00K derived: sum of 3 quarters · filed 2024-04-16 | |
| 2021-12-31 | -$175.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$236.00K derived: sum of 2 quarters · filed 2023-02-28 | -$366.00K 10-K · filed 2023-02-28 | |
| 2021-09-30 | -$61.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$191.00K 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | -$130.00K 10-Q · filed 2022-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |